Paliperidone palmitate is an atypical long acting antipsychotics，which
can fast onset in acute phase and continuously improve the symptoms in
maintenance phase． It has the solid efficacy and convenient
ad[1]ministration，which offer a new option for schizophrenia treatment
and will help patients to adhere the treatment and prevent relapse． As
the sole long acting antipsychotics with monthly injection，it was
approved by CFDA in 2011 and indicated for the acute and maintenance
treatment of schizophrenia．
ChEBI: 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl hexadecanoate is a fatty acid ester obtained by the formal condensation of the carboxy group of hexadecanoic acid with the hydroxy group of 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one. It is a member of 1,2-benzoxazoles, a heteroarylpiperidine, an organofluorine compound, a pyridopyrimidine and a fatty acid ester.
The review of the literature also underlined that paliperidone palmitate
is well tolerated, compared with placebo. Frequency and severity of
side-effects such as extrapyramidal symptoms, hyperprolactinemia and
weight gain, was similar or less than those found in treatment with
other atypical antipsychotics, including long-acting ones.
